+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Peripheral Neuropathy Market by Treatment Type (Non-Pharmacological Treatments, Pharmacological Treatments), Route of Administration (Oral, Parenteral, Topical), Age Group, End-User - Global Forecast 2025-2030- Product Image
Diabetic Peripheral Neuropathy Market by Treatment Type (Non-Pharmacological Treatments, Pharmacological Treatments), Route of Administration (Oral, Parenteral, Topical), Age Group, End-User - Global Forecast 2025-2030- Product Image
Sale

Diabetic Peripheral Neuropathy Market by Treatment Type (Non-Pharmacological Treatments, Pharmacological Treatments), Route of Administration (Oral, Parenteral, Topical), Age Group, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055283
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetic Peripheral Neuropathy Market grew from USD 4.67 billion in 2024 to USD 5.04 billion in 2025. It is expected to continue growing at a CAGR of 8.21%, reaching USD 7.51 billion by 2030.

Diabetic Peripheral Neuropathy (DPN) has emerged as a complex medical condition that poses critical challenges to healthcare systems worldwide. In recent years, increasing incidences of diabetes coupled with the chronic nature of nerve damage have propelled DPN into the spotlight, urging stakeholders to closely examine its treatment strategies, evolving patient demographics, and broader market implications. This comprehensive overview assesses the dynamic landscape of DPN, focusing on both current trends and future possibilities. Healthcare practitioners and decision-makers now rely on in-depth market intelligence to navigate the subtleties of treatment approaches and patient management. The report underscores not only the medical complexities involved in managing DPN but also emphasizes the economic repercussions and potential growth areas that arise from innovative treatment modalities. As experts delve into treatment modalities that range from non-pharmacological to pharmacological strategies, the analysis serves as a vital resource that connects research-based insights with actionable market intelligence. The discussion that follows aims to provide clarity on how these emerging dynamics are reshaping the DPN market, ensuring informed decision-making for industry professionals.

Transformative Shifts in the Landscape

The DPN market is experiencing transformative shifts driven by rapid advancements in medical research, evolving patient needs, and innovative therapeutic approaches. Recent years have witnessed a significant evolution as both emerging and established treatments vie for market prominence. There has been an increased focus on non-pharmacological methods such as acupuncture and physical therapy, aimed at providing relief with minimal side effects, whereas pharmacological treatments, including antidepressants and antiepileptics, have been at the forefront thanks to their promising efficacy. Moreover, the shift in treatment paradigms is not isolated to clinical advancements alone. Regulatory reforms and increased investments in research and development have paved the way for novel drug formulations and administration routes that offer improved patient outcomes. With improvements in diagnostic technologies and a deeper understanding of patient-specific variables such as age and underlying health conditions, the field is moving towards more personalized treatment protocols. These shifts not only reflect a growing convergence between technology and medicine but also highlight the importance of adaptive strategies in a competitive market. The evolving dynamics call for a collaborative approach, where clinicians, researchers, and policy makers work in synchrony to ensure that transformative products and practices better address patient needs.

Key Segmentation Insights

In order to grasp the full spectrum of market opportunities within the diabetic peripheral neuropathy domain, a meticulous segmentation analysis has been undertaken to unfold key insights. The segmentation based on treatment type bifurcates the market into non-pharmacological treatments, such as acupuncture and physical therapy, as well as pharmacological treatments, including tailored therapies using antidepressants and antiepileptics. This categorization highlights that non-pharmacological approaches have gained traction owing to their natural and holistic appeal, while pharmacological segments continue to dominate due to extensive clinical evidence supporting their efficacy. Further analysis based on the route of administration delineates the market into oral, parenteral, and topical medians. Notably, the parenteral category, which is additionally segmented into intramuscular and intravenous treatments, underscores the push towards methods that offer expedited therapeutic effects and improved patient compliance in acute settings. Another critical segmentation perspective considers age groups across adults, geriatrics, and pediatrics, emphasizing that treatment protocols need to be tailored to varying physiological responses and lifestyle factors associated with each group. Finally, an examination based on end-user settings - including home care settings, hospitals, and specialty clinics - reflective of the diversified application settings, underscores that market strategies must adapt to the unique operational demands and patient care models of each environment. Collectively, these segmentation insights illustrate the multifaceted nature of the market and provide a foundational framework for targeted commercialization strategies.

Based on Treatment Type, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Acupuncture and Physical Therapy. The Pharmacological Treatments is further studied across Antidepressants and Antiepileptics.

Based on Route of Administration, market is studied across Oral, Parenteral, and Topical. The Parenteral is further studied across Intramuscular and Intravenous.

Based on Age Group, market is studied across Adults, Geriatrics, and Pediatrics.

Based on End-User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics.

Key Regional Insights

Regional dynamics continue to play a pivotal role in shaping the diabetic peripheral neuropathy market. A thorough geographic analysis reveals distinct trends across several major regions. In the Americas, robust healthcare infrastructure combined with high awareness levels about diabetes-related complications propel market growth. The region shows an upward trend in adopting patient-centric care models and integrating advanced diagnostic protocols into routine clinical practice. Across Europe, the Middle East, and Africa, a blend of established healthcare systems with ongoing investments in innovative therapies have spurred advancements in both treatment and diagnosis. These regions are witnessing a gradual yet steady transition towards the incorporation of novel non-pharmacological and pharmacological treatment options tailored to specific population needs. Meanwhile, the Asia-Pacific region benefits from its large, diverse patient base and growing governmental support for healthcare reforms. With rising economic growth and heightened focus on public health, this region is poised for significant market expansion. Differences in clinical guidelines, regulatory nuances, and patient demographics in these geographies necessitate localized strategies that resonate with unique regional characteristics. Understanding such regional disparities not only aids market players in prioritizing their investments but also facilitates a more synchronized global approach to addressing diabetic peripheral neuropathy challenges.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

The competitive landscape of the diabetic peripheral neuropathy market is marked by the presence of multiple renowned companies that consistently drive innovation and quality in treatment development. Industry giants such as Abbott Laboratories, Algotherapeutix, and Artelo Biosciences, Inc. have been instrumental in pioneering advanced therapeutic modalities, thereby reinforcing the market’s strategic direction. Significant contributions from Asahi Kasei Corporation, Astellas Pharma Inc., AstraZeneca plc, and Boehringer Ingelheim GmbH continue to elevate the standards of research and patient care in this domain. Further competitive maneuvers are evident from the efforts of Boston Scientific Corporation, Bristol-Myers Squibb Company, Eisai Inc., Eli Lilly and Company, and GlaxoSmithKline plc, all of which have consistently focused on leveraging clinical insights and advanced technologies to better manage DPN. Other notable players such as Glenmark Pharmaceuticals Ltd., Grunenthal Group, Johnson & Johnson, and Lupin Limited enrich the competitive landscape by providing diversified product portfolios that address a wide spectrum of patient needs. Medtronic plc, Merck & Co., Inc., NeuroMetrix, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sorrento Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. continue to fortify the market with innovative solutions that blend efficacy and safety. Together, these companies are setting high benchmarks in R&D, ensuring that the market remains dynamic and responsive to clinical and socioeconomic shifts.

The report delves into recent significant developments in the Diabetic Peripheral Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AlgoTherapeutix, Artelo Biosciences, Inc., Asahi Kasei Corporation, Astellas Pharma Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, Eisai Inc., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Grunenthal Group, Johnson & Johnson, Lupin Limited, Medtronic plc, Merck & Co., Inc., NeuroMetrix, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sorrento Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Actionable Recommendations for Industry Leaders

In order to secure competitive advantage within the rapidly evolving diabetic peripheral neuropathy market, industry leaders need to adopt multi-dimensional strategies that align with both clinical imperatives and evolving market trends. A key recommendation is to invest in comprehensive research collaborations that blend clinical insights with the latest technological advancements. Leaders should explore partnerships with academic and research institutions to facilitate robust clinical trials of emerging therapies, particularly those that show promise in non-pharmacological treatment avenues. There is equal merit in prioritizing innovations that enhance the convenience and efficiency of drug administration, with special attention to developing formulations that cater to both the parenteral and oral administration segments. Given the nuanced demands of patients spanning various age groups and treatment settings, a tailored approach - sensitive to demographic and geographic variations - can drive market penetration. Enhancing digital engagement and employing data analytics to monitor patient response and adherence patterns can serve as an invaluable tool for fine-tuning treatment protocols over time. Moreover, strategic entry into under-served regions, particularly those within the Asia-Pacific, should be considered as an opportunity to broaden market reach. Ultimately, a coordinated emphasis on clinical efficacy, regulatory compliance, and patient-centric innovation will allow industry leaders to address both the current needs and the future trajectory of the market effectively.

The expansive review of the diabetic peripheral neuropathy market indicates that the domain is at a critical juncture, balancing clinical innovation with the imperatives of an evolving patient landscape. The increasing prevalence of diabetes, compounded by the chronic impact of nerve damage, necessitates sustained efforts in both research and application. As evidenced by transformative shifts and segmented insights, the market is not only responding to patient demands with innovative treatment modalities but is also enhancing regional and company-specific strategies aimed at improving outcomes. The integration of advanced diagnostics, personalized treatment plans, and a differentiated approach to drug delivery is reshaping the competitive landscape. Looking forward, sustained growth is contingent upon the ability of stakeholders to anticipate market trends, foster interdisciplinary collaborations, and adopt agile strategies that encompass both preventive and therapeutic measures. An integrative approach that combines clinical excellence with technological innovation will be paramount to addressing future challenges and capitalizing on emerging opportunities. The confluence of global market dynamics, strategic regional insights, and a highly competitive corporate environment underscores a future where informed decision-making and adaptive strategies prevail.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of diabetes globally
5.1.1.2. Increasing awareness among patients about complications of diabetes
5.1.1.3. Rapid adoption of advanced therapies and medications for effective management of neuropathic pain
5.1.2. Restraints
5.1.2.1. Potential adverse effects and safety concerns of new therapeutic options
5.1.3. Opportunities
5.1.3.1. Utilization of wearable technology for continuous monitoring and management of diabetic neuropathy
5.1.3.2. Innovations in telehealth solutions tailored for diabetic peripheral neuropathy patients
5.1.4. Challenges
5.1.4.1. Regulatory constraints and prolonged approval processes for diabetic peripheral neuropathy therapies
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: Increasing preference for non-pharmacological treatments due to lower side effects
5.2.2. End-User: Expanding utilization of diabetic peripheral neuropathy treatment in hospitals
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Diabetic Peripheral Neuropathy Market, by Treatment Type
6.1. Introduction
6.2. Non-Pharmacological Treatments
6.2.1. Acupuncture
6.2.2. Physical Therapy
6.3. Pharmacological Treatments
6.3.1. Antidepressants
6.3.2. Antiepileptics
7. Diabetic Peripheral Neuropathy Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
7.3.1. Intramuscular
7.3.2. Intravenous
7.4. Topical
8. Diabetic Peripheral Neuropathy Market, by Age Group
8.1. Introduction
8.2. Adults
8.3. Geriatrics
8.4. Pediatrics
9. Diabetic Peripheral Neuropathy Market, by End-User
9.1. Introduction
9.2. Home Care Settings
9.3. Hospitals
9.4. Specialty Clinics
10. Americas Diabetic Peripheral Neuropathy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Diabetic Peripheral Neuropathy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Diabetic Peripheral Neuropathy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Scenario Analysis
13.3.1. ElectroCore's strategic acquisition of NeuroMetrix aims to enhance diabetic peripheral neuropathy care
13.3.2. Orpyx secures USD 20 million funding to enhance diabetic foot ulcer prevention and enhance patient mobility
13.3.3. Alkem and Sonnet join forces for advancements in diabetic neuropathy treatment in India
13.3.4. Lexicon Pharmaceuticals and Medidata collaborate to enhance non-opioid diabetic neuropathy treatments
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DIABETIC PERIPHERAL NEUROPATHY MARKET MULTI-CURRENCY
FIGURE 2. DIABETIC PERIPHERAL NEUROPATHY MARKET MULTI-LANGUAGE
FIGURE 3. DIABETIC PERIPHERAL NEUROPATHY MARKET RESEARCH PROCESS
FIGURE 4. DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 11. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 13. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 15. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 17. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 19. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. DIABETIC PERIPHERAL NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 25. DIABETIC PERIPHERAL NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETIC PERIPHERAL NEUROPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DIABETIC PERIPHERAL NEUROPATHY MARKET DYNAMICS
TABLE 7. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. CANADA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 55. CANADA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 56. CANADA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 58. CANADA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. CANADA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. CHINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. CHINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 92. CHINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 93. CHINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. CHINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 95. CHINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. CHINA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. INDIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 99. INDIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 100. INDIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. INDIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 102. INDIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. INDIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. JAPAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. JAPAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 113. JAPAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 114. JAPAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. JAPAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 116. JAPAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. JAPAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. MALAYSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. PHILIPPINES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. SINGAPORE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. THAILAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. THAILAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 155. THAILAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 156. THAILAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. THAILAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 158. THAILAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. THAILAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 175. DENMARK DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. DENMARK DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 177. DENMARK DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 178. DENMARK DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. DENMARK DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 180. DENMARK DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. DENMARK DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. EGYPT DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. EGYPT DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 184. EGYPT DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 185. EGYPT DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. EGYPT DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 187. EGYPT DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. EGYPT DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. FINLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 191. FINLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. FINLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 194. FINLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. FRANCE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 198. FRANCE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 199. FRANCE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. FRANCE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 201. FRANCE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 202. FRANCE DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. GERMANY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 205. GERMANY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 206. GERMANY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. GERMANY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 208. GERMANY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. GERMANY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. ITALY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. ITALY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 219. ITALY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 220. ITALY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. ITALY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 222. ITALY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. ITALY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. NORWAY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. NORWAY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. POLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 247. POLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 248. POLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. POLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 250. POLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 251. POLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. QATAR DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. QATAR DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 254. QATAR DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 255. QATAR DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. QATAR DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 257. QATAR DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. QATAR DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 280. SPAIN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. SPAIN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 282. SPAIN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 283. SPAIN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. SPAIN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 285. SPAIN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. SPAIN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 287. SWEDEN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. SWEDEN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND DIABETIC PERIPHERAL NEUROPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. SWITZ

Companies Mentioned

  • Abbott Laboratories
  • AlgoTherapeutix
  • Artelo Biosciences, Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Eisai Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Grunenthal Group
  • Johnson & Johnson
  • Lupin Limited
  • Medtronic plc
  • Merck & Co., Inc.
  • NeuroMetrix, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sorrento Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.51 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Diabetic Peripheral Neuropathy- Pipeline Insight, 2024 - Product Image

Diabetic Peripheral Neuropathy- Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Diabetic Neuropathic Pain Market - Product Image

Diabetic Neuropathic Pain Market

  • Report
  • 250 Pages
  • Global
From
Diabetic Neuropathy Market by Treatment Type, Disorder Type, Distribution channel - Global Forecast 2025-2030 - Product Image

Diabetic Neuropathy Market by Treatment Type, Disorder Type, Distribution channel - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 260 Pages
  • Global
From
Diabetic Neuropathy Management Market Size, Share & Trends Analysis Report By Devices (Electrical stimulation, Neuro Stimulation Devices), By Application (Peripheral Neuropathy), By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Diabetic Neuropathy Management Market Size, Share & Trends Analysis Report By Devices (Electrical stimulation, Neuro Stimulation Devices), By Application (Peripheral Neuropathy), By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 220 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.